FDA
-
-
-
-
-
-
-
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
-
-
-
-
-
-
-
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
-
-
-
-
-
-
-
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
-
-
-
-
-
-
-
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Appoints Nicholas Grund as Chief Commercial Officer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

